Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Mainz Biomed NV MYNZ

Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.


NDAQ:MYNZ - Post by User

Post by TradeDriver718on Nov 22, 2024 3:55pm
26 Views
Post# 36326696

Mainz Biomed: Unlocking the Future of Diagnostics

Mainz Biomed: Unlocking the Future of DiagnosticsWith its low float and groundbreaking technology, MYNZ is a compelling play in the diagnostics space. Its ability to address an unmet global health need gives it a unique position for long-term growth.
<< Previous
Bullboard Posts
Next >>